ClinicalTrials.gg
CompletedNCT01562834Updated Feb 28, 2024

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

A Phase 4 interventional study of somatropin and placebo in Growth Hormone Disorder and Adult Growth Hormone Deficiency, sponsored by Novo Nordisk A/S. Completed at 24 sites in France. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 13 years 5 months after the study started (first participant enrolled Oct 1998, registered Mar 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
45th of 60
22 · median 66
Started
1998
the only one that year
Phase 4
19 of 60
none open now
Registered
42nd of 60
by date
Lead sponsor
8 of 60
Novo Nordisk A/S

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 45th largest by enrollment, is the only one that started in 1998, is one of 19 in phase 4, and was the 42nd registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to assess the effect of somatropin (Norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.

03

Conditions studied

  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Childhood or adult onset growth hormone deficiency (GHD)
  • GHD evidenced by two stimulation tests
  • Duration of GHD at least 5 years
  • Other hormone deficiencies associated with growth hormone deficiency

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or pregnancy desired during the suggested duration of the study
  • Personal history of colonic polyp or family history of colonic polyposis
  • Known insulin-dependent or non-insulin-dependent diabetes
  • Cardiovascular disease, left ventricular hypertrophy from other aetiology, recent auricular or ventricular arrhythmia, history of vascularisation by aortocoronary bypass significative mitral or aortic valvular disease, preexcitation syndrome, auriculoventricular conduction delay, bradycardia-tachycardia syndrome, left ventricular mass interfering treatment
  • (Body Mass Index) at least 30
  • Growth hormone treatment during the 24 months prior to inclusion, history of treatment with extractive pituitary growth hormone, allergy or suspected allergy to somatropin therapy
  • Patient who has participated in a different clinical study within the past two months
  • Any condition which, in the opinion of the Investigator or the Scientific Committee, may interfere with successful implementation of the study
  • Notion of breast cancer for the mother or the sister
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Somatropin

    Drug: somatropin

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.

  • Drugplacebo

    Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.

06

What researchers measure

Primary outcomes

  1. Left ventricular mass measured with ultrasonography

Secondary outcomes

  1. Ventricular function indices assessed by cardiac ultrasonography

  2. Bone mineral density and body composition assessed by DEXA (Dual Energy X-Ray Absorptiometry)

  3. Quality of life using EQ5D (European Quality of Life 5 Dimensions) scales

  4. IGF-I (Insulin-Like Growth Factor I) concentration

07

Study locations

24 sites
  • Novo Nordisk Investigational Site
    ANGERS cedex 09, 49033, France
  • Novo Nordisk Investigational Site
    Boisguillaume, 76233, France
  • Novo Nordisk Investigational Site
    Brest, 29609, France
  • Novo Nordisk Investigational Site
    Caen, 14033, France
  • Novo Nordisk Investigational Site
    Grenoble, 38043, France
  • Novo Nordisk Investigational Site
    Le Kremlin-bicetre, 94275, France
  • Novo Nordisk Investigational Site
    Lille, 59037, France
  • Novo Nordisk Investigational Site
    Lorient, 56322, France
  • Novo Nordisk Investigational Site
    Lyon, 69394, France
  • Novo Nordisk Investigational Site
    Lyon, 69437, France
  • Novo Nordisk Investigational Site
    MARSEILLE Cédex 05, 13385, France
  • Novo Nordisk Investigational Site
    MONTPELLIER cedex 5, 34295, France
  • Novo Nordisk Investigational Site
    Nantes, 44000, France
  • Novo Nordisk Investigational Site
    Nantes, 44093, France
  • Novo Nordisk Investigational Site
    Nice, 06002, France
  • Novo Nordisk Investigational Site
    Paris, 75010, France
  • Novo Nordisk Investigational Site
    Paris, 75015, France
  • Novo Nordisk Investigational Site
    Paris, 75571, France
  • Novo Nordisk Investigational Site
    Reims, 51092, France
  • Novo Nordisk Investigational Site
    Rennes, 35056, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67098, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31054, France
  • Novo Nordisk Investigational Site
    Tours, 37044, France
  • Novo Nordisk Investigational Site
    Vandoeuvre Les Nancy, 54511, France
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 1998 to primary completion in Dec 2002, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2012
First posted
Mar 26, 2012
StartActual
Oct 21, 1998
Primary completionActual
Dec 1, 2002
CompletionActual
Dec 1, 2002
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01562834
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 26, 2012
Start date
Oct 21, 1998
Primary completion
Dec 1, 2002
Completion
Dec 1, 2002
Last update
Feb 28, 2024

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion